US 11,085,080 B2Granted

Use of IL-3, IL-33 and IL-12p40 as markers for characterization of respiratory infections by respiratory syncytial virus

AssigneePontificia Universidad Catolica De Chile

InventorsAlexis Mikes Kalergis Parra, Susan Marcela Bueno Ramirez, Jose Pablo Bertrand Navarrete, Margarita Kam-Lem Lay Remolcoi

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention is related to detecting respiratory diseases using molecular markers as prognostic tool of the evolution of respiratory infection cases. Concretely, during the differential diagnostic of respiratory infections caused by the Syncytial Respiratory Virus and human Metapneumovirus, it will be established the expression pattern of the severity markers of IL-3, IL-33 and IL12p40. The expression pattern of the molecular markers can be defined in biological samplers using ELISA assays, flow cytometry or PCR in real time. The confirmation of the etiological agent of the infection in combination to the pattern definition of the molecular markers IL-3, IL-33 and IL12p40 will indicate a prognostic of the disease severity.

Claims2

Dependent claims

A method of treating a subject with a prognosis of developing recurrent wheezing or asthma after bronchiolitis caused by Respiratory Syncytial Virus (RSV), the method comprising:

(i) detecting the levels of IL-3 protein, IL-12p40 protein and IL-33 protein in a bronchoalveolar lavage fluid sample from the subject using an assay;
(ii) correlating the detected levels to the prognosis of recurrent wheezing or asthma, wherein a concentration of the IL-3 and/or IL-12p40 levels greater than 500 pg/ml is indicative of the prognosis of developing recurrent wheezing, and wherein a concentration of the IL-33 level greater than 500 pg/ml is indicative of the prognosis of developing asthma;
and
(iii) administering corticosteroid to the subject with the prognosis of developing recurrent wheezing or asthma, wherein the subject is an infant under 12 months of age, and is tested positive for RSV.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 15/748,984Filed 25 Jul 2016
Priority: CL 20150215331 Jul 2015
Published: US 2018/0327843 A115 Nov 2018
Granted: 10 Aug 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
A61P 11/06
Drugs for disorders of the respiratory system: antiasthmatics
G01N 33/6893
Involving proteins, peptides or amino acids: related to diseases not provided for elsewhere
C12Q 2600/112
Oligonucleotides characterized by their use: disease subtyping, staging or classification